Novigenix is working with radiopharmaceutical company RadioMedix to develop a molecular test that can detect neuroendocrine tumors early and predict treatment response.
The test will be based on Novigenix's proprietary LITOseek liquid biopsy platform, which is designed for the development and testing of predictive gene signatures for immune response in blood, with the aid of artificial intelligence algorithms. The company said it has a database of immuno-transcriptome profiles from hundreds of cancer patients and healthy people that can be used to detect cancer early, as well as to predict and monitor response to treatment.
The new diagnostic will help manage patients treated with RadioMedix's alpha and beta peptide receptor radionuclide therapy (PRRT). In a statement, Novigenix said the plan is to develop a test that is useful "across the entire course of treatment and follow-up." Approximately 12,000 people in the U.S. are diagnosed with neuroendocrine tumors every year, and 170,000 are living with the condition, the company noted. Diagnosis entails imaging and endoscopy studies.
